Skip to main content
SpringerLink
Log in
Book cover

Targeting Oral Cancer pp 283–299Cite as

Mucosal Therapy for Potentially Malignant Diseases and OSCC

  • Chapter
  • First Online:

Abstract

Despite remarkable advances in our ability to manage and treat a number of hematologic and solid malignancies, there has been a paucity of new chemotherapeutic agents to significantly improve the outcomes and survival of oral cavity squamous cell carcinoma (OSCC) patients (Furness et al., Cochrane Database Syst Rev (4):CD006386, 2011). Surgical resection and radiation and systemic chemotherapy are first-line options used in the management of most patients. The cure rate for early-stage OCSS patients remains very promising; however, these lifesaving surgeries are often accompanied by tremendous sacrifices. Many patients are left with cosmetic and functional disfigurement and require adjunctive support for basic functions such as chewing, swallowing, and, in some cases, even breathing. The exploration of local delivery methods, such as mucosal therapy, holds promise due to decreased systemic toxicity, consequently decreased morbidity, and improved patient quality of life (Saba et al., Oral Oncol 51:112–118, 2015). Furthermore, topical therapies offer an alternative in the treatment of malignant precursor lesions, such as leukoplakia and erythroplakia, so that patients may be treated earlier and remain in the purview of nonsurgical oral healthcare providers.

Peter F. Svider and Blake M. Warner contributed equally.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev. 2011;(4):CD006386. Epub 2011/04/15.

    Google Scholar 

  2. Saba NF, Haigentz Jr M, Vermorken JB, Strojan P, Bossi P, Rinaldo A, et al. Prevention of head and neck squamous cell carcinoma: removing the “chemo” from “chemoprevention”. Oral Oncol. 2015;51(2):112–8. Epub 2014/12/02.

    Article  PubMed  Google Scholar 

  3. Iyer NG, Tan DS, Tan VK, Wang W, Hwang J, Tan NC, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599–607. Epub 2015/02/03.

    Article  PubMed  Google Scholar 

  4. Weatherspoon DJ, Chattopadhyay A, Boroumand S, Garcia I. Oral cavity and oropharyngeal cancer incidence trends and disparities in the United States: 2000–2010. Cancer Epidemiol. 2015;39(4):497–504. Epub 2015/05/16.

    Article  PubMed  Google Scholar 

  5. Canto MT, Devesa SS. Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998. Oral Oncol. 2002;38(6):610–7. Epub 2002/08/09.

    Article  PubMed  Google Scholar 

  6. Jacobson JJ, Epstein JB, Eichmiller FC, Gibson TB, Carls GS, Vogtmann E, et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol. 2012;4:15. Epub 2012/04/28.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Epstein JD, Knight TK, Epstein JB, Bride MA, Nichol MB. Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population. Head Neck. 2008;30(2):178–86. Epub 2007/08/19.

    Article  PubMed  Google Scholar 

  8. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–42. Epub 2013/04/27.

    Google Scholar 

  9. Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122(8):741–6. Epub 2009/06/09.

    Article  PubMed  Google Scholar 

  10. Munoz Guerra MF, Naval Gias L, Campo FR, Perez JS. Marginal and segmental mandibulectomy in patients with oral cancer: a statistical analysis of 106 cases. J Oral Maxillofac Surg. 2003;61(11):1289–96.

    Article  PubMed  Google Scholar 

  11. Mohit-Tabatabai MA, Sobel HJ, Rush BF, Mashberg A. Relation of thickness of floor of mouth stage I and II cancers to regional metastasis. Am J Surg. 1986;152(4):351–3.

    Article  PubMed  Google Scholar 

  12. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992;81(1):1–10. Epub 1992/01/01.

    Article  PubMed  Google Scholar 

  13. Birudaraj R, Mahalingam R, Li X, Jasti BR. Advances in buccal drug delivery. Crit Rev Ther Drug Carrier Syst. 2005;22(3):295–330. Epub 2005/05/18.

    Article  PubMed  Google Scholar 

  14. Collins LM, Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Res. 1987;66(8):1300–2. Epub 1987/08/01.

    Article  PubMed  Google Scholar 

  15. Paderni C, Compilato D, Giannola LI, Campisi G. Oral local drug delivery and new perspectives in oral drug formulation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(3):e25–34. Epub 2012/07/10.

    Article  PubMed  Google Scholar 

  16. Gavin A, Pham JT, Wang D, Brownlow B, Elbayoumi TA. Layered nanoemulsions as mucoadhesive buccal systems for controlled delivery of oral cancer therapeutics. Int J Nanomedicine. 2015;10:1569–84. Epub 2015/03/12.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004;101(12):2837–42.

    Article  PubMed  Google Scholar 

  18. Pindborg JJ, Roed-Peterson B, Renstrup G. Role of smoking in floor of the mouth leukoplakias. J Oral Pathol. 1972;1(1):22–9.

    Article  PubMed  Google Scholar 

  19. Wirth LJ. Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum. Cancer Prev Res (Phila). 2014;7(3):279–82.

    Article  Google Scholar 

  20. Holpuch AS, Desai KG, Schwendeman SP, Mallery SR. Optimizing therapeutic efficacy of chemopreventive agents: a critical review of delivery strategies in oral cancer chemoprevention clinical trials. J Carcinog. 2011;10:23. Epub 2011/10/21.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.

    Article  PubMed  Google Scholar 

  22. Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 1996;25(2):49–54.

    Article  PubMed  Google Scholar 

  23. Jaiswal G, Jaiswal S, Kumar R, Sharma A. Field cancerization: concept and clinical implications in head and neck squamous cell carcinoma. J Exp Ther Oncol. 2013;10(3):209–14.

    PubMed  Google Scholar 

  24. Binmadi NO, Basile JR. Perineural invasion in oral squamous cell carcinoma: a discussion of significance and review of the literature. Oral Oncol. 2011;47(11):1005–10.

    Article  PubMed  Google Scholar 

  25. Huang SH, O’Sullivan B. Oral cancer: current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013;18(2):e233–40.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Does adjuvant radiation therapy improve outcomes in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? Int J Radiat Oncol Biol Phys. 2008;71(2):371–6.

    Article  PubMed  Google Scholar 

  27. Fan KH, Wang HM, Kang CJ, Lee LY, Huang SF, Lin CY, et al. Treatment results of postoperative radiotherapy on squamous cell carcinoma of the oral cavity: coexistence of multiple minor risk factors results in higher recurrence rates. Int J Radiat Oncol Biol Phys. 2010;77(4):1024–9.

    Article  PubMed  Google Scholar 

  28. Irune E, Dwivedi RC, Nutting CM, Harrington KJ. Treatment-related dysgeusia in head and neck cancer patients. Cancer Treat Rev. 2014;40(9):1106–17.

    Article  PubMed  Google Scholar 

  29. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–31.

    Article  PubMed  Google Scholar 

  30. Squier CA. The permeability of oral mucosa. Crit Rev Oral Biol Med. 1991;2(1):13–32.

    PubMed  Google Scholar 

  31. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5):991–4.

    PubMed  Google Scholar 

  32. Wang ZM, Liu J, Liu HB, Ye M, Zhang YF, Yang DS. Abnormal COX2 protein expression may be correlated with poor prognosis in oral cancer: a meta-analysis. BioMed Res Int. 2014;2014:364207. Epub 2014/07/17.

    PubMed Central  PubMed  Google Scholar 

  33. Renkonen J, Wolff H, Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch. 2002;440(6):594–7.

    Article  PubMed  Google Scholar 

  34. Mallery SR, Zwick JC, Pei P, Tong M, Larsen PE, Shumway BS, et al. Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions. Cancer Res. 2008;68(12):4945–57. Epub 2008/06/19.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Goodin S, Shiff SJ. NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al. randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565–1573, 2004. Clin Cancer Res. 2004;10(5):1561–4.

    Article  PubMed  Google Scholar 

  36. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7(11):1163–70.

    Article  PubMed  Google Scholar 

  37. Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev. 1994;13(3–4):303–8.

    Article  PubMed  Google Scholar 

  38. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):493–501.

    Article  PubMed  Google Scholar 

  39. Kast RE. Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation. Mol Immunol. 2003;40(5):297–303.

    Article  PubMed  Google Scholar 

  40. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res. 2005;11(5):2089–96. Epub 2005/03/10.

    Article  PubMed  Google Scholar 

  41. Chen X, Zhang X, Lu Y, Shim JY, Sang S, Sun Z, et al. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol. Nutr Cancer. 2012;64(8):1211–8. Epub 2012/11/10.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Sun Z, Sood S, Li N, Ramji D, Yang P, Newman RA, et al. Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis. 2006;27(9):1902–8. Epub 2006/04/25.

    Article  PubMed  Google Scholar 

  43. Sudbo J, Lee JJ, Lippman SM, Mork J, Sagen S, Flatner N, et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case–control study. Lancet. 2005;366(9494):1359–66.

    Article  PubMed  Google Scholar 

  44. Cornwall H, Odukoya O, Shklar G. Oral mucosal tumor inhibition by ibuprofen. J Oral Maxillofac Surg. 1983;41(12):795–800.

    Article  PubMed  Google Scholar 

  45. Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol. 1981;107(11):658–63.

    Article  PubMed  Google Scholar 

  46. Sood S, Shiff SJ, Yang CS, Chen X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol. 2005;41(6):562–7.

    Article  PubMed  Google Scholar 

  47. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004;10(5):1565–73.

    Article  PubMed  Google Scholar 

  48. Shirasuna K, Hayashido Y, Sugiyama M, Yoshioka H, Matsuya T. Immunohistochemical localization of epidermal growth factor (EGF) and EGF receptor in human oral mucosa and its malignancy. Virchows Arch A Pathol Anat Histopathol. 1991;418(4):349–53.

    Article  PubMed  Google Scholar 

  49. Reeves TD, Hill EG, Armeson KE, Gillespie MB. Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. Otolaryngol Head Neck Surg. 2011;144(5):676–84.

    Article  PubMed  Google Scholar 

  50. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  PubMed  Google Scholar 

  51. Roy HK, Kunte DP, Koetsier JL, Hart J, Kim YL, Liu Y, et al. Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/beta-catenin signaling. Mol Cancer Ther. 2006;5(8):2060–9. Epub 2006/08/25.

    Article  PubMed  Google Scholar 

  52. Roy HK, Gulizia J, DiBaise JK, Karolski WJ, Ansari S, Madugula M, et al. Polyethylene glycol inhibits intestinal neoplasia and induces epithelial apoptosis in Apc(min) mice. Cancer Lett. 2004;215(1):35–42. Epub 2004/09/18.

    Article  PubMed  Google Scholar 

  53. Corpet DE, Parnaud G. Polyethylene-glycol, a potent suppressor of azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis. 1999;20(5):915–8. Epub 1999/05/20.

    Article  PubMed  Google Scholar 

  54. Wali RK, Kunte DP, Koetsier JL, Bissonnette M, Roy HK. Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail. Mol Cancer Ther. 2008;7(9):3103–11. Epub 2008/09/16.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Wali RK, Kunte DP, De La Cruz M, Tiwari AK, Brasky J, Weber CR, et al. Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response. PLoS One. 2012;7(6):e38047. Epub 2012/06/08.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Sun Z, Sood S, Li N, Yang P, Newman RA, Yang CS, et al. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases. Oral Oncol. 2008;44(7):652–7.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Gorsky M, Epstein JB. The effect of retinoids on premalignant oral lesions: focus on topical therapy. Cancer. 2002;95(6):1258–64.

    Article  PubMed  Google Scholar 

  58. Epstein JB, Gorsky M. Topical application of vitamin A to oral leukoplakia: a clinical case series. Cancer. 1999;86(6):921–7.

    Article  PubMed  Google Scholar 

  59. Holpuch AS, Phelps MP, Desai KG, Chen W, Koutras GM, Han BB, et al. Evaluation of a mucoadhesive fenretinide patch for local intraoral delivery: a strategy to reintroduce fenretinide for oral cancer chemoprevention. Carcinogenesis. 2012;33(5):1098–105. Epub 2012/03/20.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res. 1997;57(14):2890–5.

    PubMed  Google Scholar 

  61. Ki Hong W, Lippman SM, Hittelman WN, Lotan R. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res. 1995;1(7):677–86.

    PubMed  Google Scholar 

  62. Scher RL, Saito W, Dodge RK, Richtsmeier WJ, Fine RL. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines. Otolaryngol Head Neck Surg. 1998;118(4):464–71.

    PubMed  Google Scholar 

  63. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 1995;332(21):1405–10.

    Article  PubMed  Google Scholar 

  64. Piattelli A, Fioroni M, Santinelli A, Rubini C. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study. Oral Oncol. 1999;35(3):314–20.

    Article  PubMed  Google Scholar 

  65. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315(24):1501–5.

    Article  PubMed  Google Scholar 

  66. Tete S, Pappalardo S, Rubini C, Salini L, Falco A, Perfetti EG. The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin. Minerva Stomatol. 1999;48(9):411–8.

    PubMed  Google Scholar 

  67. Wong F, Epstein J, Millner A. Treatment of oral leukoplakia with topical bleomycin. A pilot study. Cancer. 1989;64(2):361–5.

    Article  PubMed  Google Scholar 

  68. Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head Neck. 1994;16(6):539–44.

    Article  PubMed  Google Scholar 

  69. Epstein JB, Gorsky M, Wong FL, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer. 1998;83(4):629–34.

    Article  PubMed  Google Scholar 

  70. Giannola LI, De Caro V, Giandalia G, Siragusa MG, Paderni C, Campisi G, et al. 5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa. Curr Drug Deliv. 2010;7(2):109–17.

    Article  PubMed  Google Scholar 

  71. Grant WE, Hopper C, Speight PM, Macrobert AJ, Bown SG. Photodynamic therapy of malignant and premalignant lesions in patients with ‘field cancerization’ of the oral cavity. J Laryngol Otol. 1993;107(12):1140–5. Epub 1993/12/01.

    Article  PubMed  Google Scholar 

  72. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250–81. Epub 2011/05/28.

    Article  PubMed Central  PubMed  Google Scholar 

  73. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–7. Epub 2003/05/02.

    Article  PubMed  Google Scholar 

  74. Jerjes W, Upile T, Akram S, Hopper C. The surgical palliation of advanced head and neck cancer using photodynamic therapy. Clin Oncol (R Coll Radiol). 2010;22(9):785–91. Epub 2010/09/11.

    Article  Google Scholar 

  75. Jerjes W, Upile T, Hamdoon Z, Abbas S, Akram S, Mosse CA, et al. Photodynamic therapy: The minimally invasive surgical intervention for advanced and/or recurrent tongue base carcinoma. Lasers Surg Med. 2011;43(4):283–92. Epub 2011/04/19.

    Article  PubMed  Google Scholar 

  76. Vohra F, Al-Kheraif AA, Qadri T, Hassan MI, Ahmed A, Warnakulasuriya S, et al. Efficacy of photodynamic therapy in the management of oral premalignant lesions. A systematic review. Photodiagnosis Photodyn Ther. 2015;12(1):150–9. Epub 2014/10/16.

    Article  PubMed  Google Scholar 

  77. Yu CH, Chen HM, Hung HY, Cheng SJ, Tsai T, Chiang CP. Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion. Oral Oncol. 2008;44(6):595–600. Epub 2008/01/22.

    Article  PubMed  Google Scholar 

  78. Yu CH, Lin HP, Chen HM, Yang H, Wang YP, Chiang CP. Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light. Lasers Surg Med. 2009;41(9):628–33. Epub 2009/10/10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology, Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Peter F. Svider MD

  2. Karmanos Cancer Institute, Detroit, MI, USA

    Peter F. Svider MD & Andrew M. Fribley PhD

  3. Division of Oral and Maxillofacial Pathology, Department of Diagnostic Sciences, University of Pittsburgh, School of Dental Medicine, Pittsburgh, PA, 151216, USA

    Blake M. Warner DDS, PhD, MPH

  4. Fribley-Callaghan Collaboratory, Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Scott J. Schwartz & Danielle M. Garshott BS

  5. Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Danielle M. Garshott BS

  6. Marshall University School of Medicine, 1109 Woodland Drive, Bridgeport, WV, USA

    James D. Weinstein MD (Professor of Neuroscience (Retired)

  7. Fribley-Callaghan Collaboratory, Wayne State University School of Medicine, Detroit, MI, USA

    Andrew M. Fribley PhD

  8. Division of Hematology Oncology, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA

    Andrew M. Fribley PhD

  9. Department of Otolaryngology, Head and Neck Surgery, Wayne State University School of Medicine, 421 E. Canfield, Room 2228, Detroit, MI, USA

    Andrew M. Fribley PhD

  10. Molecular Therapeutics Group, Karmanos Cancer Institute, Detroit, MI, USA

    Andrew M. Fribley PhD

Authors
  1. Peter F. Svider MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blake M. Warner DDS, PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott J. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Danielle M. Garshott BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James D. Weinstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew M. Fribley PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter F. Svider MD .

Editor information

Editors and Affiliations

  1. School of Medicine, Wayne State University, DETROIT, Michigan, USA

    Andrew M. Fribley

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Svider, P.F., Warner, B.M., Schwartz, S.J., Garshott, D.M., Weinstein, J.D., Fribley, A.M. (2016). Mucosal Therapy for Potentially Malignant Diseases and OSCC. In: M. Fribley, A. (eds) Targeting Oral Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27647-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27647-2_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27645-8

  • Online ISBN: 978-3-319-27647-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation